| 5.54 0.04 (0.73%) | 07-14 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.79 | 1-year : | 9.09 |
| Resists | First : | 6.67 | Second : | 7.79 |
| Pivot price | 5.16  |
|||
| Supports | First : | 4.77 | Second : | 3.59 |
| MAs | MA(5) : | 5.36 |
MA(20) : | 5.09 |
| MA(100) : | 4.69 |
MA(250) : | 4.95 |
|
| MACD | MACD : | 0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 62.5 |
D(3) : | 60.1 |
| RSI | RSI(14): 54.4 |
|||
| 52-week | High : | 9.85 | Low : | 2.96 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ NDRA ] has closed below upper band by 34.5%. Bollinger Bands are 22.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.91 - 5.95 | 5.95 - 5.99 |
| Low: | 5.25 - 5.29 | 5.29 - 5.32 |
| Close: | 5.4 - 5.46 | 5.46 - 5.5 |
ENDRA Life Sciences Inc. specializes in advancing the capabilities of clinical diagnostic ultrasound. The company's primary development is thermo-acoustic enhanced ultrasound technology, which operates by emitting sound waves that echo off internal body components such as tissues, organs, and blood. This innovation is utilized in managing nonalcoholic fatty liver disease, meticulously monitoring temperature during thermoablative surgical procedures, detailed vascular imaging, and assessing tissue perfusion. Furthermore, ENDRA offers other diagnostic imaging modalities, including computed tomography (CT), magnetic resonance imaging (MRI), and conventional ultrasound. These instruments empower physicians to visualize internal anatomy, aiding in treatment guidance and the identification of various medical conditions like bone fractures, cancerous growths, indicators of heart disease, or internal bleeding. The company also maintains a research collaboration agreement with General Electric Company. Established in 2007, ENDRA Life Sciences Inc. is headquartered in Ann Arbor, Michigan.
Thu, 25 Jun 2026
ENDRA Life Sciences Inc. Actuals & Estimates (NASDAQ:NDRA) - TradingView
Thu, 25 Jun 2026
[144] ENDRA Life Sciences Inc. SEC Filing - Stock Titan
Thu, 25 Jun 2026
ASP Isotopes' Noble Africa unit to merge with ENDRA Life Sciences unit in $50M deal (ASPI:NASDAQ) - Seeking Alpha
Thu, 25 Jun 2026
ENDRA Life Sciences (NDRA) proposes merger of subsidiary with Noble Africa - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 1 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 8.7 (%) |
| Held by Institutions | 9.6 (%) |
| Shares Short | 42 (K) |
| Shares Short P.Month | 20 (K) |
| EPS | -8.35 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.44 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -122.4 % |
| Return on Equity (ttm) | -412.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -5.07 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -5 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.66 |
| PEG Ratio | 0 |
| Price to Book value | 3.78 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.39 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|